| 2.14 0.04 (1.9%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.69 | 1-year : | 3.16 |
| Resists | First : | 2.3 | Second : | 2.71 |
| Pivot price | 1.87 |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 2.02 |
| MA(100) : | 1.03 |
MA(250) : | 0.74 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 29 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 2.71 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IPSC ] has closed below upper band by 0.4%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.18 | 2.18 - 2.18 |
| Low: | 2.01 - 2.02 | 2.02 - 2.03 |
| Close: | 2.12 - 2.14 | 2.14 - 2.15 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Wed, 11 Feb 2026
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Expands By 320.2% - MarketBeat
Mon, 09 Feb 2026
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race - Seeking Alpha
Tue, 03 Feb 2026
Century Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20 - Nasdaq
Sun, 01 Feb 2026
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Fri, 30 Jan 2026
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 25.4 (%) |
| Held by Institutions | 114.7 (%) |
| Shares Short | 807 (K) |
| Shares Short P.Month | 246 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.03 |
| Profit Margin | -23.4 % |
| Operating Margin | -20 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.09 |
| Sales Per Share | 1.29 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -112 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -6.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.04 |
| Price to Sales | 1.65 |
| Price to Cash Flow | -1.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|